Sinovac Biotech, Ltd
SVASinovac Biotech, Ltd (SVA) is a Chinese biopharmaceutical company focused on the development, manufacturing, and commercialization of vaccines for infectious diseases. Founded in 2001, Sinovac primarily produces vaccines for hepatitis A and B, influenza, and other viral illnesses. The company has gained global recognition for its COVID-19 vaccine, CoronaVac, which has been used in numerous countries worldwide. Sinovac operates research and manufacturing facilities in China, and its products are distributed internationally.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| July 7, 2025 | $55.00 | 2025-07-08 | 2025-05-23 |
Dividends Summary
- Consistent Payer: Sinovac Biotech, Ltd has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held SVA shares during this period received a total of $55.00 per share in dividend income.
- Latest Payout: The most recent dividend of $55.00/share was paid 376 days ago, on July 7, 2025.
Company News
Sinovac Biotech Ltd. (NASDAQ: SVA) is facing a crisis as its external auditor has resigned, leading to a delay in filing its annual report with the SEC. The company's current board is reviewing actions taken by the former board, causing uncertainty and disruption to the company's operations and governance.
The global respiratory disease vaccine market is expected to grow from $94.6 billion in 2024 to $101.56 billion by 2030, driven by factors such as the increasing prevalence of respiratory diseases, the aging population, and government vaccine mandates and recommendations.
The global influenza vaccine market is expected to grow from $6.7 billion in 2023 to $12.5 billion by 2032, driven by rising influenza cases, government initiatives, and the development of more effective vaccines.
Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale Sernova announces research collaboration with Professor Antonia Follenzi, expert in Hemophilia A at the University of Piemonte Orientale
LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today presented interim positive results from its ongoing Phase 1/2 clinical trial investigating islet allotransplantation into pre-vascularized Sernova Cel...
